| Dr Johnathan D Mcginn, MD | |
|
500 University Dr, Hershey, PA 17033-2360 | |
| (717) 531-6822 | |
| (717) 531-4907 |
| Full Name | Dr Johnathan D Mcginn |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 29 Years |
| Location | 500 University Dr, Hershey, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831156728 | NPI | - | NPPES |
| 0018405140006 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD073298L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Milton S Hershey Medical Center | Hershey, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Milton S Hershey Medical Center Physicians Group | 3870405483 | 1400 |
News Archive
Officials from the Substance Abuse and Mental Health Services Administration (SAMHSA), the Ad Council and the Stay Strong Foundation will unveil a national public service campaign designed to raise awareness of mental health problems among young adults in the African American community. The event is part of Black History Month and it is being held to coincide with the first annual Historically Black Colleges and Universities National Mental Health Awareness Day. The launch will be telecast to colleges and universities nationwide.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
HIV/AIDS clinicians and scientists have been "witness to a transformation in disease management that is virtually unprecedented in the history of medicine," Mark Wainberg, director of McGill University's AIDS Centre at Jewish General Hospital, and Julio Montaner, director of the BC Centre for Excellence in HIV/AIDS, write in a National Post opinion piece.
A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.
Paralympic medallists are supporting Fight for Sight's massive adventure on a small scale, with the launch of a unique virtual event today for National Eye Health Week 2018.
› Verified 4 days ago
| Entity Name | The Milton S Hershey Medical Center Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710951744 PECOS PAC ID: 3870405483 Enrollment ID: O20040225000741 |
News Archive
Officials from the Substance Abuse and Mental Health Services Administration (SAMHSA), the Ad Council and the Stay Strong Foundation will unveil a national public service campaign designed to raise awareness of mental health problems among young adults in the African American community. The event is part of Black History Month and it is being held to coincide with the first annual Historically Black Colleges and Universities National Mental Health Awareness Day. The launch will be telecast to colleges and universities nationwide.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
HIV/AIDS clinicians and scientists have been "witness to a transformation in disease management that is virtually unprecedented in the history of medicine," Mark Wainberg, director of McGill University's AIDS Centre at Jewish General Hospital, and Julio Montaner, director of the BC Centre for Excellence in HIV/AIDS, write in a National Post opinion piece.
A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.
Paralympic medallists are supporting Fight for Sight's massive adventure on a small scale, with the launch of a unique virtual event today for National Eye Health Week 2018.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Johnathan D Mcginn, MD Po Box 858, Mc A410, Hershey, PA 17033-0858 Ph: (800) 243-1455 | Dr Johnathan D Mcginn, MD 500 University Dr, Hershey, PA 17033-2360 Ph: (717) 531-6822 |
News Archive
Officials from the Substance Abuse and Mental Health Services Administration (SAMHSA), the Ad Council and the Stay Strong Foundation will unveil a national public service campaign designed to raise awareness of mental health problems among young adults in the African American community. The event is part of Black History Month and it is being held to coincide with the first annual Historically Black Colleges and Universities National Mental Health Awareness Day. The launch will be telecast to colleges and universities nationwide.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
HIV/AIDS clinicians and scientists have been "witness to a transformation in disease management that is virtually unprecedented in the history of medicine," Mark Wainberg, director of McGill University's AIDS Centre at Jewish General Hospital, and Julio Montaner, director of the BC Centre for Excellence in HIV/AIDS, write in a National Post opinion piece.
A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.
Paralympic medallists are supporting Fight for Sight's massive adventure on a small scale, with the launch of a unique virtual event today for National Eye Health Week 2018.
› Verified 4 days ago
Neerav Goyal, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-8521 | |
Dr. Scott Walen, M.D., FRCSC Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 Fax: 717-531-4907 | |
Dr. Jessyka G Lighthall, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 | |
Dr. Mark E. Whitaker, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-6822 Fax: 717-531-4907 | |
Sohrab Sohrabi, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 | |
Irina Chaikov, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-8521 | |
Heather Schopper, Otolaryngology Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 |